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Abstract: 
Cholesterol plays a strategic role in liposome composition, however the quantity used to 
achieve an appropriate formulation has not been yet clarified. Therefore, by screening arrange 
of lipids and cholesterol ratio, the main aim of this study is to investigate the most suitable 
amount of cholesterol in lipids in order to prepare stable and controlled drug release vehicles. 
For the preparation of liposomes, DMPC, DPPC and DSPC phospholipids were used and 
combined with different molar ratios of cholesterol (e.g. 100%, 80-20%, 70-30%, 60-40%, 
50-50%). Stability studies were conducted storing the formulations at 37oC and 50oC for 30 
days and by analysing them by AFM, DLS and FT-IR. By detecting the two most stable 
formulations from the stability results, drug encapsulation and in vitro release studies in PBS 
were performed by encapsulating Atenolol and Quinine. The release results were validated 
using a simulation model to ensure the reliability and suitable interpretation of the data. The 
generated model showed a good correlation between the prediction and the in vitro obtained 
results. By using 70:30% ratio (known in literature as 2:1), is possible to reach the most 
stable formulation to guarantee a controlled and reproducible release for drugs with different 
physicochemical characteristics and pharmaceutical applications. 
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1. Introduction 
Liposomes or ³OLSLG ERGLHV´ >1] are microstructures composed of a bilayer of natural or 
synthetic lipids [2], which arrange in polar head group and long hydrophobic tail (e.g. 
phospholipid or lecithin) forming an amphipathic environment. Moreover, liposomes pack 
concentrically around the hydrophilic and lipophilic portions being roughly equal obtaining 
DQ LQWHULRU ³YDFXROH´ ZKLFK FDQ VHUYH DV D VWRUDJH FRPSDUWPHQW IRU an active agent. The 
presence of this unique structure is suitable for encapsulation of drugs with different 
lipophilicities such as strongly lipophilic or hydrophilic drugs, and drugs with intermediate 
log P [3], providing solutions for drug delivery. Liposomes have been extensively 
investigated for drug targeting [4] [5], drug delivery [6] [7], controlled release [8], and 
increased solubility [9]. However, the major rate-limiting step in the use of this versatile drug 
delivery system is the physical and chemical stability of the liposome [1]. In phospholipid 
bilayers two types of chemical degradation reactions can affect the performance of the 
liposomes, hydrolysis of the ester bonds linking the fatty acids to the glycerol backbone and 
the peroxidation of unsaturated acyl chains (if present). The oxidation and hydrolysis of lipids 
may lead to the appearance of short-chain lipids, and then soluble derivatives will form in the 
membrane which can result a decrease in the quality of liposome products [10]. Moreover, 
physical processes such as aggregation/flocculation and fusion/coalescence, can affect the 
shelf life of liposomes due to loss of liposome associated drug and changes in size. It is 
detectable that the stability can affect the performances of liposomes. Therefore, the control 
over their physical stability becomes an important prerequisite for the effective use of 
liposomes as a drug carrier [11], and any change in particle size of carriers can affect 
targeting, safety and efficacy [1]. It is important to guarantee a good stability of liposomes in 
terms of rigidity of the lipid bilayer by selecting lipids with a high phase transition 
temperature (Tc), which is affected by fatty acid side chains, degree of unsaturation, chain 
length and polar head groups [12]. In this study phosphatidylcholine (PC) liposomes were 
selected since are lipids with long acyl chain length (DMPC: 14 C; DPPC: 16 C; DSPC: 18 
C), unsaturated and consequently with a high transition temperature.  
  
A very important variant in the liposomal structure that could control the stoutness is the 
content of cholesterol. Numerous studies on the use of cholesterol as a stabilizer were 
conducted, showing that this steroid can: (1) increase the packing of phospholipid molecules 
[13], (2) reduce bilayer permeability to non-electrolyte and electrolyte solutes [14], (3) 
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improve vesicle resistance to aggregation [15], (4) change the fluidity of intravesicle 
interactions make them more rigid and sustain in sever shear stress of the lipid bilayer [16], 
and (5) reduce drug incorporation efficiency [17]. The maximum amount of cholesterol that 
has been reported and can be incorporated into reconstituted bilayers is widely assumed to be 
about 50 mol %, [18] [19] [20]. However, the ratio between cholesterol and lipid used to 
reach the more stable and more efficient formulation is not well clarified. The most 
frequently used proportion is a 2:1 ratio (e.g. 2 parts of lipids and 1 part of cholesterol) or 1:1 
ratio; however, the reason for this particular ratio is unknown. To understand this preference, 
this paper will investigate a greater variety of ratios and different storage temperatures by 
using Atomic Force Microscopy (AFM), Dynamic Light Scattering (DLS), and Fourier 
Transform Infrared Spectroscopy (FTIR), in order to either confirm that this is the optimum 
ratio for liposome stability or to find a better alternative. Additionally, after the stability 
studies, the article will focus the attention on release of two drugs with different 
physicochemical characteristics that loaded into the two ³best´ liposome formulations. The 
drugs selected were Atenolol (A) as hydrophilic model and Quinine (Q) as hydrophobic 
H[DPSOH 7KH\ EHORQJ WR ȕ-blocker and antimalarial class respectively providing an 
interesting study of controlled release for two classes of drugs that largely used and 
confirming the wide range of liposomes application as drug delivery systems. Furthermore, in 
order to ensure an accurate interpretation of the results, the drug release studies were 
validated using a mathematical model, demonstrating its utility in extracting reliable rate 
constants where different drug bindings can affect the apparent release kinetics. 
  
2. Materials and Methods 
2.1. Materials 
The synthetic lipids 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC) and 1,2-Distearoyl-sn-glycero-3-phosphocholine 
(DSPC) were a gift from Lipoid GmbH (Fig. 1). Cholesterol (CH), Atenolol (A) and Quinine 
(Q) were obtained from Sigma-Aldrich. 
 
2.2. Preparation of liposomes 
Liposomes were prepared using the film hydration method as previously described by 
Bangham et al.[21], by mixing a variety of lipids and using different ratio of lipid/cholesterol 
(100% of lipids, 80:20%, 70:30%, 60:40%, 50:50%). The mixture of lipid and cholesterol 
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was dissolved in chloroform and then it was dried up to a thin lipid film under vacuum using 
a rotatory evaporator (Heidolph, Germany). For the stability studies the liposomes were 
prepared without adding drug solution, thus the dry lipid film was rehydrated with phosphate 
buffered saline (PBS) in order to obtain a lipid suspension. The liposomes used to analyse the 
drug release were prepared by rehydrating the thin lipid film with the drug solution (10 mg 
mL-1Atenolol and 0.45 mg mL-1 Quinine).The liposome solution in both cases was divided 
into three Eppendorf tubes and it was sonicated for 30 min in a VWR ultrasonic cleaner. 
Following sonication in accordance with literature, the liposome suspensions were left to 
stand for 1 h at a temperature higher than the transition temperature of the lipid used in each 
case (e.g. 40°C DMPC, 50°C DPPC, 70°C DSPC), in order to anneal any structural defects 
[22]. The top liquid layer was removed leaving the deposited liposomes at the bottom of the 
centrifuge tube. In order to conduct the stability studies of formed liposomes the centrifuge 
product was rehydrated with PBS and was used for liposome characterisation.  
 
2.3. Liposomes Physicochemical Characterization 
 
2.3.1. Dynamic Light Scattering (DLS) 
The size distribution (mean diameter and polydispersity index) and the zeta (ȗ) potential of 
the liposomes were measured by DLS on a ZetasizerNano-ZS (Malvern Instruments Ltd., 
UK), which enabled to obtain the mass distribution of particle size as well as the 
electrophoretic mobility. Measurements were made at 25 °C with a fixed angle of 137 °. 
Sizes quoted are the z-average mean (dz) for the liposomal hydrodynamic diameter (nm). 
 
2.3.2. Fourier Transform Infrared Spectroscopy (FTIR) 
All the excipients such as DMPC, DPPC, DSPC, and cholesterol were analysed separately 
with infrared (IR). The pellets were scanned in an inert atmosphere over a wave number 
range of 3000-1500 cm-1 over 128 scans at a resolution of 4 cmí1 and an interval of 1 cmí1. 
All FT-IR spectra were recorder on a Nicolet iS10 (ThermoScientific) Smart iTR 
spectrophotometer and each spectrum was background subtracted. 
 
2.3.3. Atomic Force Microscopy (AFM) 
A volume of 5 µl from each liposome and liposome-cholesterol mixture was placed on a 
freshly cleaved mica surface (1.5 cm x 1.5 cm; G250-0LFDVKHHWV´[´[´$JDU
Scientific Ltd., Essex, UK). Each aliquot was kept on the mica surface for 5 minutes and then 
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washed wiWKORIZDWHU 0LOOLSRUH0FP7KHVDPSOHZDV WKHQDLU-dried and 
imaged at once by scanning the mica surface in air under ambient conditions using a Bruker 
MultiMode8 Scanning Probe Microscope (Digital Instruments, Santa Barbara, CA, USA) 
operated in tapping mode. AFM measurements were obtained using soft silicon probes 
(FESP; nominal length 225 µm, width 28 µm, tip radius 8nm, resonant frequency 75 kHz, 
spring constant 2.8 N/m; Bruker Instruments SAS, Dourdan, France). AFM scans were 
acquired at a resolution of 512 x 512 pixels and produced topographic images of the samples 
in which the brightness of features increases as a function of height. Typical scanning 
parameters were as follows: tapping frequency 73 kHz, RMS amplitude before engage 1 V, 
integral and proportional gains 0.3 and 0.5 respectively, set point 0.4 ± 0.7 V, and scanning 
speed 1.0 Hz. Surface roughness (Ra) values were determined by entering surface scanning 
data into a digital levelling algorithm (Nanoscope Analysis 1.5) and the particle size 
(diameter) are determined using Nanoscope Analysis 1.5 image processing software which 
obtained height patterns and cross sections of the lipid nanoparticles. AFM images were 
collected from two different samples and at random spot surface sampling (minimum of 5 
areas) by counting more than 50 liposomes.  
 
2.3.4. Dialysis dynamic experiment 
Dynamic dialysis is one of the most commonly used methods for the determination of release 
kinetics from nanoparticles [23]. Prior to the addition of the mixture, the dialysis tube 
(0LOOLSRUH  0ȍ FP was placed in boiling water for 30 min and rinsed with copious 
amount of water. After the pre-treatment, following a dynamic dialysis procedure described 
by Joguparthi et al. [24] a volume of 1 mL of liposomal suspension was added into the 
dialysis bag tying both ends and suspending the tube in 5 mL PBS at pH 7.4 [25].  
 
2.4. Drug release experiment 
Drug release was analysed by extraction of 400µL aliquots of the immersion medium at 
intervals of 15 min, 30 min, 1, 2, 3, 4, 24, 48, 72 h and 7, 14 days at 37oC and at 7.4 pH. To 
satisfy the perfect-sink conditions and keeping the volume of the solution constant, the 
supernatant was replaced with fresh PBS pre-equilibrated at 37°C at each time point allowing 
the determination of the diffusion parameters. The amount of drug released at each time point 
was determined by UV-Vis using a Varian 50 bio UV-visible spectrophotometer at room 
temperature. The concentration of the drug released from the dialysis tube was determined 
using a calibration curve of the pure drugs in PBS solutions at the wavelength where showed 
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the maximum absorbance (Atenolol: 224nm [26] and Quinine: 250nm [27]).The absorbance 
was converted into percentage release using a standard curve and experiments were 
performed in triplicates in order to ensure accuracy. 
 
2.5. Mathematical Modelling and Simulation 
Data fitting and simulation were done on previously developed mathematical models [24] 
[28]. Thus, the considered equation was: 
 ெ೟ெಮ ൌ ݇ଵݐ௠+ ݇ଶݐଶ௠Eq.1 (Model developed by Peppas and Sahlin) 
 
Where t represents the time, k1, k2 and m are constants. Mt/M represents the Fickian 
diffusional contribution considering the amount of drug released at time t and infinite time. 
These parameters were used as the initial input in Igor Pro 6.34A to refine the estimations 
using an optimization method. 
 
3. Results and Discussion 
 
3.1. Particle size measurements 
The size distribution is a key aspect to consider in the characterization of liposomes. In order 
to get more detailed and quantitative understanding of the stabilization effect of the different 
quantities of cholesterol added to the lipids, DLS was used. The temperature selected to 
conduct the analysis with empty liposomes were 37oC as the human body temperature, and 
50oC that is particularly significant for the antimalarial release study. The stability studies 
were carried out for 30 days, showing in all experiments the same performances (Figs.2-4), 
and liposomes prepared without cholesterol (Fig.5) at both temperatures show an unstable but 
expected behaviour.  
 
Using the film hydration method to manufacture the liposomes no filtration or extrusion 
procedures [29] were performed for all set of experiments proving values of mean diameter 
above 200 nm both with and without cholesterol. Concerning the only lipid formulation, the 
size range presents the values of mean diameter: DMPC (297.45 ± 9.5 nm); DPPC (305.6 ± 
8.6 nm); DSPC (385.2 ± 7.8 nm). Regarding the highest mixture of lipid and cholesterol (50-
50%), the size range presents the diameter: DMPC (292.5 ± 3.8 nm); DPPC (289.0 ±5.6 nm); 
DSPC (362.7± 5.6nm). 
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Looking at the stability, especially for DMPC, the formulation manufactured using only lipid 
(Fig. 2a), is clearly altered because of the transition temperature (Tc) of 23oC (Table 1). It is 
obvious to link the unstable performance of DMPC without cholesterol to the temperature 
chosen to conduct the analyses. At 37oC and 50oC, DMPC liposomes are above the Tc and 
the bilayer is in a more fluid liquid crystalline phase [34]. Membrane chain melting properties 
are regulated by the polar surface of the lipid bilayer, reducing the stability and creating a 
different arrangement in structures where aggregation can occur. In pure DPPC and DSPC 
the Tc are 41oC and 54oC, respectively, guarantying a more orderly behaviour. Although not 
ideal (Fig.5 b-c), since the first addition of cholesterol in ratio 80:20 the light scattering 
showed a clear reduction in size, identifying an average of the diameters for DMPC (268.9 ± 
6.8 nm), DPPC (255.6 ± 10.3 nm), and DSPC (360.6 ± 6.7 nm). These results demonstrate 
that by introducing cholesterol into the lipid bilayer, a more stable trend was detected 
reaching the aim of increasing the state of order. Gradually the amount of cholesterol 
incorporated in the liposomes was improved causing an increase also in terms of the sizes as 
in consistent with the literature [16]. Furthermore, looking at the ȗ-potential results [DMPC 
100% (0.87 ± 0.12), DMPC 70%-30% (-0.50 ± 0.13)], [DPPC 100% (0.92 ± 0.16), DPPC 
70%-30% (-0.41 ± 0.25)], and [DSPC 100% (0.79 ± 0.11), DSPC 70%-30% (-0.71 ± 0.18)], 
it is clear that the ȗ-potential values are approximately zero for all 100% lipids samples and 
converts to negative, improving particles stability when the amount of cholesterol is been 
increased. 
 
The important rule of cholesterol in liposome formulation is evident from the stability profile 
of DMPC data. Fig.2 shows an improvement of the chord lengths distribution with the 
gradually enhancement of cholesterol, which tends to raise the Tc obtaining a range of 
temperature where the membrane elasticity modulus is much larger [35] [32] and it can affect 
the liposomes size [37]. 
 
For each lipid combinations investigated, the two more stable formulations were chosen to 
make a further study by using Atenolol and Quinine in order to analyse their drug release. 
The selected combinations were: DMPC 70:30% and 50:50%, DPPC 0:30% and 60:40%, and 
DSPC 70:30% and 60:40%. Confirming what the literature asserts, the ratio 70:30%,which 
represents the proportion 2:1, is the common mixture in all cholesterol/PC formulations. 
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3.2. AFM 
AFM is a rapid, powerful and relatively non-invasive technique that was used in this study to 
investigate the effects of cholesterol concentration on the liposomes adsorbed on mica surface 
providing a characterization about shape, morphology and surface properties. Since lipids are 
soft samples the tapping mode procedure was used; it consists in an intermittent contact 
between the cantilever and the sample in order to reduce frictional and adhesive forces, which 
would deform or scrape the sample [38][39].Amplitude images of the PC and PC/cholesterol 
(ratio 70:30 molar) are shown in Fig 6. However, AFM results for PC/cholesterol molar ratio 
50:50 and 60:40 are not reported because the quality of the obtained images did not permitted 
an appreciable analysis on the individual vesicle. The liposome suspensions incubated with 
the highest content of cholesterol, in accordance with Liang [40] appeared blurred without 
show a visible sphericity, providing the suggestion that the best combination to reach a 
perfect formulation of liposomes is the 70:30ratios. Considering the images carried out from 
the sample without cholesterol (Fig.6 a,c,e), it is possible to confirm the instability of 
liposomal formulation on mica surface. 
 
The cloudy area clearly visible in Fig.6c is characterized by a flattened layer of lipids with 
high viscosity, which can be related to collapse lipids and not well assembled to the rest of 
the liposomal structure [41]. Moreover, when cholesterol is added to the lipid bilayer (Fig. 6 
b,d,f), the images refer spherical and well-defined structure confirming the essential rule of 
the cholesterol in the liposome formulations in order to increase the state of order. However, 
knowing from the literature that despite the tapping mode application, liposomes can change 
their shape once deposited on mica support inducing deformations [42] depending chiefly on 
the vesicle composition [43], a comparison between AFM results and DLS data was 
performed in order to validate the analysis (Table 2). In AFM detection, the most common 
problem is the collapse of lipids, however despite that Kanno et al. [44] demonstrated that the 
diameter acquired by AFM measurements can be compared with the size obtained using DLS 
analysis evaluating the differences. According to DLS, AFM reveals a difference in terms of 
reduction of particle size for lipids modified with cholesterol [45]. Furthermore, the 
formulation with ratio 70-30% for each lipid analysed, which shows small standard deviation, 
suggesting well-assembled structure.  
 
3.3. FT-IR 
The variation on cholesterol concentrations are causing changes in the liposomal membrane 
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structure, producing various frequencies of vibrational modes [46]. Therefore, the 
characterisation of the liposome formulations using FTIR was performed in order to 
understand the cholesterol interaction with phospholipids. A comparative study between the 
pure lipid and formulated liposomes is shown in Fig.7. 
 
The strongest bands at 2920 cmí1 and 2850 cmí1 represent the CH2 symmetric and 
antisymmetric stretch modes [47], and the peak around 1740 cm-1 characterizes the C=O 
stretch of the ester bond, where the fatty acid chain meets the head group [48]. FTIR spectra 
have been compared considering the increase of cholesterol amount which changes the 
detected signal. The gradual addition of cholesterol provides a regular loss of information, 
showing a disturbed signal in the region clearly detected previously. For each lipid where the 
added cholesterol was 50% (DMPC) or 40% (DPPC and DSPC) the detection of peaks was 
possible, especially in the region around 1740 cm-1 since cholesterol provides a steric 
hindrance hiding the C=O stretch. These results represent an additional prove that the 70:30 
ratio represents the most suitable compromise to increase the stability without alter the lipid 
composition. 
 
3.4. Encapsulation efficiency 
After stability and characterisation studies the two drug molecules A and Q were 
encapsulated in the two most stable detected formulations of DMPC, DPPC and DSPC. The 
factors that are affecting the encapsulation efficiency (%EE) of the drug in the liposomes are 
various and originated from the liposomes and the loaded drug properties [49]. Concerning 
the encapsulated molecules, the %EE is affected by hydrophilic or hydrophobic properties, 
and also the interaction with the membrane bilayer is subjected to changes of different 
amount of cholesterol. The %EE was calculated using the formula in Eq.2:  ? ܧܧ ൌ ௐ೟ௐ೔  ? ? ?  Eq.2 
Where Wt is the total amount of drug in the liposomes suspension and Wi is the total quantity 
of drug added initially during preparation. Table 3 shows the %EE results for all formulation 
combinations; it can be observed for both drugs (A and Q) that by increasing the incorporated 
% of cholesterol the amount of drug loaded LW¶V EHHQ reduced. Despite the different 
physicochemical characteristics of the chosen compounds, the %EE results are relatively high 
for both compounds demonstrating how the film method used to prepare liposomes had been 
produced a possible link to the polar head for A and to the non-polar chains for Q. 
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Previous works had demonstrated a competitive action within the liposomal bilayers between 
drugs and amount of cholesterol on the incorporation of drugs [50] [51]. The literature reports 
the capacity of cholesterol to increase the hydrophobicity of the membranes, which can 
favour the inclusion of hydrophobic molecules [52]. However, it must be considered the 
conflicting fact that cholesterol favours to accommodate into the lipophilic bilayer structure, 
which is represented by lipid chains [17]. Cases with high presence of cholesterol cause 
limited space for Q accommodation [Fig.8, a] due to the steric hindrance provided by the 
steroid reducing the %EE. 
 
Cholesterol is been affected also by the hydrophilic drug encapsulation, despite the 
interaction that occurs with the phosphate heads, which can be explained as a steric hindrance 
reason. Increasing the amount of cholesterol such as DMPC or DPPC 50-50% and DSPC 60-
40%, the chosen hydrophilic druJ $ ZLOO KDYH OLPLWHG ³ELQGLQJ VSDFH´ ZKHUH LW Fan be 
linked to the drug delivery. Moreover, when the formulation is prepared using a reduced 
quantity of cholesterol, 30% rather than 50% or 40%, the %EE value was increased. The 
results present encapsulation efficacy of 90% for A and 88% for Q, demonstrating how a 
reproducible high level of loaded drugs can be reached using a molar ratio of 70-30%, which 
represents a good equilibrium between flexibility furnished by lipids and the stability that 
ensured by cholesterol. 
 
3.5. Drug release 
The drug release is illustrated in Fig. 9 as a plot of mass released fraction (Mt/M) vs time 
(t).The drug release was measured for A and Q using the following formulation:DMPC 70:30 
and 50:50 (Fig.9a), DPPC 70:30 and 50:50 (Fig.9b), and DSPC 70:30 and 50:50 (Fig.9c).  
 
Despite the different physicochemical characteristics of the two studied drugs (one 
hydrophilic and one hydrophobic) and the different lipid/ cholesterol combinations, common 
performances were detected for each type of lipids.1) The hydrophilic drug (A) is released 
faster than hydrophobic drug (Q), 2) the formulation with the higher amount of cholesterol 
when A was loaded had recorded the faster release, 3) the combination with a higher amount 
of cholesterol when Q was added had shown the slower release, and 4) an initial burst release 
was observed as expected at an incubation temperature of 37oC [53].  
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The analysis of the drug delivery was furthermore conducted comparing drug release, particle 
size and content of cholesterol, underling how cholesterol affects both stability and drug 
release performances (Fig.10). 
 
For all liposomes, the reduction of cholesterol showed a decrease of particle size and 
different trend on drug release. These performances can be traced to the physicochemical 
properties of the selected organic compounds and to the competitive action between drugs 
and cholesterol [17]. As explained in section 3.4, cholesterol affects the release of A, since 
the hydrophilic drug interact with the head of liposome. Increasing the cholesterol quantity 
(DMPC 50-50%, DPPC 60-40% and DSPC 60-40%), A will have less encapsulated amount 
and the release will be faster. On the other hand, considering the location of the hydrophobic 
drug (Q) which interacts with the long chain of each type of lipids, the augmented presence 
of cholesterol will cause a less encapsulation efficacy and a reduced release action since the 
steric hindrance. In accordance with drug release results, the best combination of lipids and 
cholesterol is represented by 70-30% reaching a sustained, controlled and reproducible 
release. The release rates were measured in sink conditions; otherwise the evaluation of the 
drug release from liposomal dispersions will be problematic due to the dependence of the 
analysis from the test conditions [54]. In the traditional dialysis technique, the carrier is 
suspended in a small volume of continuous phase and separated from a sink solution by 
permeable dialysis membrane [55] providing a physical separation between nanoparticles and 
free drug at various time points during the kinetic study. The validation of the drug release 
model was obtained making assumptions to justify the mathematical model used, for 
example: 1) analysis is based on one-dimensional diffusion, thus edge effects must be 
negligible; 2) the suspended drug is in a fine state that particles are much smaller in diameter 
than the thickness of the system; 3) the diffusivity of the drug is constant; 4) perfect sink 
conditions are maintained; and  WKH DSSHDUDQFH RI GUXJ LQ WKH ³VLQN´ LV WKH UHVXOW RI WKH
diffusion from the nanoparticles followed by diffusion across the dialysis membrane (though 
it is generally treated as a simple first order process). Considering all these assumption, using 
Eq.1 and Igor Pro 6.34A, a model validation was performed by comparing the predicted drug 
release with experiment data (Fig.11). 
 
Results demonstrated a good correlation between the measured drug release profile and the 
prediction, indicating the validity of the model. The mathematical modelling provides a 
scientific tool to verify the design parameters on the resulting drug release kinetics. 
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4. Conclusions 
The main objective of this study was to investigate the best combination of lipids / 
cholesterol ration for the formulation of liposomes in order to achieve an appropriate stability 
profile, and sustained and controlled drug release. Using three types of lipids (DMPC, DPPC 
and DSPC) and different amounts of cholesterol (e.g. 50%, 40%, 30%, 20%, and 0%), a wide 
range of formulations were prepared. Storing the formed liposomes under two different 
temperatures (e.g. 37oC and 50oC) the stability of the formulations was tested and it was 
demonstrated by DLS and AFM that cholesterol is required in order to provide a well-
organized structure and a stable formulation. Using the stability results as criteria of choose, 
the two most stable formulations for each lipid used [DMPC (50-50% and 70%-30%), DPPC 
(60-40% and 70%-30%) and DSPC (60-40% and 70-30%)].Then Atenolol and Quinine were 
added proving an additional tool to understand the influence of cholesterol in drug release 
studies. A validation of the drug release using a mathematical model was obtained ensuring 
the proper interpretation of the data. The generated model showed a good correlation between 
the prediction and the in vitro results for each formulation investigated. DLS, AFM, %EE and 
drug release analysis concluded that the 2:1 ratio (70% of lipids and 30% of cholesterol) is 
the most suitable combination in terms of characterisation and as the most flexible 
formulation, in order to permit the release of drugs with different physiochemical 
characteristics. This work has confirmed the preference of literature using 2:1 as molar ratio 
in liposomes formulation and has also added extra information and explanations ensuring a 
rational understanding on the reasons that the particular combination represents the most 
frequently used.  
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Table Captions: 
Table 1. Summary of the key features of the materials that have been used. 
Table 2. Particle size results from DLS and AFM. 
Table 3. Encapsulation Efficacy of Atenolol and Quinine in each lipid formulation. 
 
Figures Captures: 
 
Fig. 1. Chemical structures of the compounds used: a) DMPC, b) DPPC, c) DSPC, d) 
Cholesterol, e) Atenolol (A), and f) Quinine (Q). 
 
Fig. 2. Size distribution of DMPC liposomes with different lipid/cholesterol ratiounder 
different temperature conditions: a) 100% lipid, b) 80%-20%, c) 70%-30%, d) 60%-40%, and 
e) 50%-50%. In all graphs the continuous line displays the size distribution at 37oC and the 
dashed line shows the size distribution at 50oC. 
Fig. 3. Size distribution of DPPC liposomes with different lipid/cholesterol ratio under 
different temperature conditions: a) 100% lipid, b) 80%-20%, c) 70%-30%, d) 60%-40%, and 
e) 50%-50%. In all graphs the continuous line displays the size distribution at 37oC and the 
dashed line shows the size distribution at 50oC. 
Fig. 4. Size distribution of DSPC liposomes with different lipid/cholesterol ratio under 
different temperature conditions: a) 100% lipid, b) 80%-20%, c) 70%-30%, d) 60%-40%, and 
e) 50%-50%. In all graphs the continuous line displays the size distribution at 37oC and the 
dashed line shows the size distribution at 50oC. 
Fig. 5. Size distribution of liposomes prepared without cholesterol: a) DMPC, b) DPPC and 
c) DSPC. 
Fig. 6. AFM images of a) DMPC, b) DMPC-Cholesterol (70-30), c) DPPC, d) DPPC-
Cholesterol (70-30), e) DSPC, and f) DSPC-Cholesterol (70-30). 
Fig. 7. FTIR spectra of a) DMPC, b) DPPC, and c) DSPC.  
 
Fig. 8. Schematic model for the encapsulation efficacy of Atenolol (a) and Quinine (b). 
Fig. 9. Drug release through dialysis tube of DMPC (a), DPPC (b), and DSPC (c). 
Fig. 10. Average particle size (bars, left axis) and % drug release after 2 weeks (dots, right 
axis) of different liposome composition. 
Fig. 11. Validation of drug release from DMPC (a), DPPC (b), and DSPC (c), using 
mathematical modelling. 
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Table 1 
 
Molecules Purity Temperature lipid transition Log P 
DMPC  23oC[30] - 
DPPC  41oC[31] - 
DSPC  54oC[32] - 
Cholesterol  - - 
Atenolol  - 0.16[33] 
Quinine  - 3.44[33] 
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Table 2 
 
Lipid Formulation (lipid / cholesterol) DLS / nm AFM / nm 
DMPC 
100% 297 ± 9.7 267 ± 4.9 
70 ± 30 % 273 ± 2.9 251 ± 4.1 
DPPC 
100% 305 ± 8.6 284 ± 6.6 
70 ± 30 % 270 ± 1.9 230 ± 2.2 
DSPC 
100% 388 ± 5.3 301 ± 3.6 
70 ± 30 % 367 ± 2.9 247 ± 1.8 
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Table 3 
 
 
Lipid Formulation (lipid / cholesterol) 
Atenolol 
%EE 
Quinine 
%EE 
DMPC 
70 ± 30 % 90.15 88.13 
50 ± 50 % 87.73 84.72 
DPPC 
70 ± 30 % 90.15 88.53 
 60 ± 40 % 88.60 84.07 
DSPC 
70 ± 30 % 91.56 87.54 
 60 ± 40 % 88.78 85.60 
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Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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Fig. 6 
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Fig. 8 
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Fig. 9 
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Fig. 10 
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Fig. 11 
 
 
